Your browser doesn't support javascript.
loading
Polygenic risk for schizophrenia converges on alternative polyadenylation as molecular mechanism underlying synaptic impairment.
Raabe, Florian J; Hausruckinger, Anna; Gagliardi, Miriam; Ahmad, Ruhel; Almeida, Valeria; Galinski, Sabrina; Hoffmann, Anke; Weigert, Liesa; Rummel, Christine K; Murek, Vanessa; Trastulla, Lucia; Jimenez-Barron, Laura; Atella, Alessia; Maidl, Susanne; Menegaz, Danusa; Hauger, Barbara; Wagner, Eva-Maria; Gabellini, Nadia; Kauschat, Beate; Riccardo, Sara; Cesana, Marcella; Papiol, Sergi; Sportelli, Vincenza; Rex-Haffner, Monika; Stolte, Sebastian J; Wehr, Michael C; Salcedo, Tatiana Oviedo; Papazova, Irina; Detera-Wadleigh, Sevilla; McMahon, Francis J; Schmitt, Andrea; Falkai, Peter; Hasan, Alkomiet; Cacchiarelli, Davide; Dannlowski, Udo; Nenadic, Igor; Kircher, Tilo; Scheuss, Volker; Eder, Matthias; Binder, Elisabeth B; Spengler, Dietmar; Rossner, Moritz J; Ziller, Michael J.
Afiliação
  • Raabe FJ; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Hausruckinger A; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Gagliardi M; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), 80804 Munich, Germany.
  • Ahmad R; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Almeida V; Department of Psychiatry, University of Münster, 48149 Münster, Germany.
  • Galinski S; Department of Psychiatry, University of Münster, 48149 Münster, Germany.
  • Hoffmann A; Center for Soft Nanoscience, University of Münster, 48149 Münster, Germany.
  • Weigert L; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Rummel CK; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Murek V; Institute of Biology, University of Campinas (UNICAMP), Campinas, São Paulo, Brazil.
  • Trastulla L; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Jimenez-Barron L; Systasy Bioscience GmbH, 81669 Munich, Germany.
  • Atella A; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Maidl S; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Menegaz D; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Hauger B; International Max Planck Research School for Translational Psychiatry (IMPRS-TP), 80804 Munich, Germany.
  • Wagner EM; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Gabellini N; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Kauschat B; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Riccardo S; Department of Psychiatry, University of Münster, 48149 Münster, Germany.
  • Cesana M; Center for Soft Nanoscience, University of Münster, 48149 Münster, Germany.
  • Papiol S; Lab for Genomics of Complex Diseases, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Sportelli V; Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Rex-Haffner M; Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Stolte SJ; Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Wehr MC; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Salcedo TO; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Papazova I; Telethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
  • Detera-Wadleigh S; NEGEDIA (Next Generation Diagnostic), Pozzuoli, Italy.
  • McMahon FJ; Telethon Institute of Genetics and Medicine (TIGEM), Armenise/Harvard Laboratory of Integrative Genomics, Pozzuoli, Italy.
  • Schmitt A; Department of Advanced Biomedical Sciences, University of Naples "Federico II", Naples, Italy.
  • Falkai P; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Hasan A; Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Cacchiarelli D; Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, 80336 Munich, Germany.
  • Dannlowski U; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Nenadic I; Department of Translational Research in Psychiatry, Max Planck Institute of Psychiatry, 80804 Munich, Germany.
  • Kircher T; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Scheuss V; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Eder M; Systasy Bioscience GmbH, 81669 Munich, Germany.
  • Binder EB; Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, 80336 Munich, Germany.
  • Spengler D; Department of Psychiatry, Psychotherapy, and Psychosomatics, Medical Faculty, University of Augsburg, 86156 Augsburg, Germany.
  • Rossner MJ; Human Genetics Branch, National Institute of Mental Health Intramural Research Program (NIMH-IRP), Bethesda, MD, 20892, USA.
  • Ziller MJ; Human Genetics Branch, National Institute of Mental Health Intramural Research Program (NIMH-IRP), Bethesda, MD, 20892, USA.
bioRxiv ; 2024 Jan 13.
Article em En | MEDLINE | ID: mdl-38260577
ABSTRACT
Schizophrenia (SCZ) is a genetically heterogenous psychiatric disorder of highly polygenic nature. Correlative evidence from genetic studies indicate that the aggregated effects of distinct genetic risk factor combinations found in each patient converge onto common molecular mechanisms. To prove this on a functional level, we employed a reductionistic cellular model system for polygenic risk by differentiating induced pluripotent stem cells (iPSCs) from 104 individuals with high polygenic risk load and controls into cortical glutamatergic neurons (iNs). Multi-omics profiling identified widespread differences in alternative polyadenylation (APA) in the 3' untranslated region of many synaptic transcripts between iNs from SCZ patients and healthy donors. On the cellular level, 3'APA was associated with a reduction in synaptic density of iNs. Importantly, differential APA was largely conserved between postmortem human prefrontal cortex from SCZ patients and healthy donors, and strongly enriched for transcripts related to synapse biology. 3'APA was highly correlated with SCZ polygenic risk and affected genes were significantly enriched for SCZ associated common genetic variation. Integrative functional genomic analysis identified the RNA binding protein and SCZ GWAS risk gene PTBP2 as a critical trans-acting factor mediating 3'APA of synaptic genes in SCZ subjects. Functional characterization of PTBP2 in iNs confirmed its key role in 3'APA of synaptic transcripts and regulation of synapse density. Jointly, our findings show that the aggregated effects of polygenic risk converge on 3'APA as one common molecular mechanism that underlies synaptic impairments in SCZ.

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: BioRxiv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: BioRxiv Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Alemanha